Suppr超能文献

在艾姆斯试验中使用人肝S9的优势。

Advantage of the use of human liver S9 in the Ames test.

作者信息

Hakura A, Suzuki S, Satoh T

机构信息

Drug Safety Research Laboratories, Eisai Co., Ltd., 1-3 Tokodai, 5-chome, Tsukuba, Ibaraki 300-26, Japan.

出版信息

Mutat Res. 1999 Jan 2;438(1):29-36. doi: 10.1016/s1383-5718(98)00159-4.

Abstract

The mutagenicity of 13 chemicals was compared using human liver S9 or liver S9 prepared from male Sprague-Dawley rats either non-treated (R-n) or pretreated with phenobarbital/5,6-benzoflavone (R-i). The test compounds used in this study were well recognized procarcinogens requiring cytochrome P450 for metabolic activation. These included polycyclic aromatic hydrocarbons, aromatic amines, heterocyclic aromatic amines, nitrosoamines, and nitropyrene. We used four human liver S9 fractions, one of which was prepared from the liver sample having higher levels of the P450-catalyzed drug metabolizing enzyme activities, a possible explanation for which was enzyme induction by anti-asthma agents for 10 years. The results of the present study are as follows: (1) there were individual differences in the magnitude of the mutagenic activity of the procarcinogens by each S9 fraction used, (2) equivalent mutagenicity of chemicals was seen with three human S9 fractions (H3, H8, and H12), while a human H14 S9 fraction showed higher P450 enzyme activity, leading to much higher mutagenicity than the other three human S9 specimens, (3) the order of magnitude of the mutagenicity of the procarcinogens using human and rat liver S9 fractions was R-i>/=H14>/=R-n>/=H3, H8, and H12, while with 2-aminoanthrathene, N-nitrosodimethylamine, and 1-nitropyrene, this relationship was H3, H8, H12, and H14>/=R-n>/=R-i. The experimental data in the present study strongly suggest that the complementary use of human liver S9 fraction in the Ames test is a much more useful tool than rat S9 for evaluation of genotoxicity to humans.

摘要

使用人肝脏S9或从未处理(R-n)或用苯巴比妥/5,6-苯并黄酮预处理(R-i)的雄性Sprague-Dawley大鼠制备的肝脏S9,比较了13种化学物质的致突变性。本研究中使用的受试化合物是公认的前致癌物,需要细胞色素P450进行代谢活化。这些包括多环芳烃、芳香胺、杂环芳香胺、亚硝胺和硝基芘。我们使用了四个人肝脏S9组分,其中一个是从具有较高水平P450催化的药物代谢酶活性的肝脏样本中制备的,对此的一个可能解释是抗哮喘药物诱导酶达10年之久。本研究结果如下:(1)每种使用的S9组分对前致癌物的致突变活性大小存在个体差异;(2)三种人S9组分(H3、H8和H12)对化学物质的致突变性相当,而人H14 S9组分显示出较高的P450酶活性,导致其致突变性比其他三个人S9样本高得多;(3)使用人和大鼠肝脏S9组分时,前致癌物致突变性的大小顺序为R-i≥H14≥R-n≥H3、H8和H12,而对于2-氨基蒽、N-亚硝基二甲胺和1-硝基芘,这种关系为H3、H8、H12和H14≥R-n≥R-i。本研究中的实验数据有力地表明,在艾姆斯试验中互补使用人肝脏S9组分比大鼠S9是评估对人类遗传毒性更有用的工具。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验